Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Investigational New Drugs|September 24, 2009
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumorsCharles J Nock, Joanna M Brell, Joseph A Bokar, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 2, 2021
Asian American/Pacific Islander and Hispanic Ethnic Enclaves, Neighborhood Socioeconomic Status, and Hepatocellular Carcinoma Incidence in California: An UpdateMeera Sangaramoorthy, Juan Yang, Alice Guan, et al.
Journal of Racial and Ethnic Health Disparities|November 15, 2022
Neighborhood Factors Associated with COVID-19 Cases in CaliforniaDebora L Oh, Dan Meltzer, Katarina Wang, et al.
American Journal of Epidemiology|December 11, 2024
Neighborhood Racial and Ethnic Composition Typology and Breast Cancer Risk: The Multiethnic Cohort StudyMeera Sangaramoorthy, Yuqing Li, Joseph Gibbons, et al.
The Oncologist|September 28, 2013
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreasCheng Ean Chee, Smitha Krishnamurthi, Charles J Nock, et al.
Investigational New Drugs|June 20, 2020
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumorsJennifer R Eads, Smitha S Krishnamurthi, Joel Saltzman, et al.
Cancer Chemotherapy and Pharmacology|April 17, 2008
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabineSmitha S Krishnamurthi, Joanna M Brell, Charles L Hoppel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Ebiomedicine|March 4, 2021
Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infectionCharlotte Manisty, Thomas Alexander Treibel, Melanie Jensen, et al.
Pageof 4